- Home
- HBAN vs INSM Comparison
HBAN vs INSM Comparison
Compare HBAN & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBAN
- INSM
- Stock Information
- Founded
- HBAN 1866
- INSM 1988
- Country
- HBAN United States
- INSM United States
- Employees
- HBAN N/A
- INSM N/A
- Industry
- HBAN Major Banks
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- HBAN Finance
- INSM Health Care
- Exchange
- HBAN Nasdaq
- INSM Nasdaq
- Market Cap
- HBAN 23.6B
- INSM 26.0B
- IPO Year
- HBAN N/A
- INSM 2000
- Fundamental
- Price
- HBAN $16.01
- INSM $127.80
- Analyst Decision
- HBAN Buy
- INSM Strong Buy
- Analyst Count
- HBAN 17
- INSM 17
- Target Price
- HBAN $18.72
- INSM $137.40
- AVG Volume (30 Days)
- HBAN 32.8M
- INSM 3.0M
- Earning Date
- HBAN 10-16-2025
- INSM 08-07-2025
- Dividend Yield
- HBAN 3.74%
- INSM N/A
- EPS Growth
- HBAN 26.38
- INSM N/A
- EPS
- HBAN 1.34
- INSM N/A
- Revenue
- HBAN $7,242,000,000.00
- INSM $398,105,000.00
- Revenue This Year
- HBAN $17.91
- INSM $28.23
- Revenue Next Year
- HBAN $7.87
- INSM $119.99
- P/E Ratio
- HBAN $12.37
- INSM N/A
- Revenue Growth
- HBAN 7.91
- INSM 21.15
- 52 Week Low
- HBAN $11.92
- INSM $60.40
- 52 Week High
- HBAN $18.45
- INSM $128.48
- Technical
- Relative Strength Index (RSI)
- HBAN 41.26
- INSM 85.01
- Support Level
- HBAN $15.82
- INSM $106.54
- Resistance Level
- HBAN $16.33
- INSM $128.48
- Average True Range (ATR)
- HBAN 0.32
- INSM 4.11
- MACD
- HBAN -0.09
- INSM 1.68
- Stochastic Oscillator
- HBAN 22.31
- INSM 97.41
About HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with around $208 billion in assets and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.